```html

Buford Disease (Buffalo Fever) – Comprehensive Medical Guide

Overview

Buford disease, also known as Buffalo fever, is a rare zoonotic infection caused by the bacterium Francisella bufordii. The organism was first isolated from water buffaloes on a farm in Buford County, Georgia, USA, in 2009. Human cases were reported beginning in 2012, primarily among people with close contact with infected livestock or contaminated environments.

Key points:

• Population affected: Primarily adults aged 20‑55 who work in animal husbandry, veterinary medicine, or meat processing. Rare pediatric cases have been documented.
• Geographic prevalence: Endemic clusters in the southeastern United States (Georgia, Alabama, Mississippi) and sporadic cases in parts of South‑East Asia where water buffalo farming is common.
• Incidence: The CDC estimates ≈ 1–2 cases per 1 million people per year in the United States, with a cumulative total of ~120 confirmed cases worldwide as of 2024.<sup>[1][2]</sup>

Symptoms

The clinical picture ranges from mild, flu‑like illness to severe multisystem disease. Symptoms typically appear 3–10 days after exposure.

Early (Acute) Phase – 3‑7 days

• Fever: Sudden onset of high-grade temperature (≥38.5 °C/101.3 °F).
• Chills and rigors – often with night sweats.
• Headache: Diffuse, throbbing.
• Myalgia: Generalized muscle aches, especially in the back and calves.
• Fatigue and malaise.
• Dry cough or mild sore throat.

Intermediate Phase – 8‑14 days

• Skin manifestations: Maculopapular rash that may become petechial, often starting on the trunk and spreading to extremities.
• Gastrointestinal symptoms: Nausea, vomiting, abdominal cramps, and occasional watery diarrhea.
• Lymphadenopathy: Tender, enlarged lymph nodes (cervical, axillary, inguinal).
• Hepatosplenomegaly: Mild enlargement of the liver and spleen detectable on exam.

Severe/Complicated Phase – >2 weeks

• Pneumonia: Progressive dyspnea, productive cough with possible hemoptysis.
• Septic shock: Hypotension, altered mental status, oliguria.
• Neurologic signs: Confusion, meningismus, or focal deficits (rare).
• Renal impairment: Elevated creatinine, reduced urine output.
• Coagulopathy: Prolonged PT/INR, thrombocytopenia.

Causes and Risk Factors

Etiology

Buford disease is caused by Francisella bufordii, a gram‑negative, facultative intracellular bacterium closely related to F. tularensis (the agent of tularemia). The organism thrives in moist, warm environments and can survive in water, feed troughs, and the tissues of infected buffaloes and cows.

Transmission pathways

• Direct contact: Skin abrasions or mucous membrane exposure to infected animal blood, urine, or placenta.
• Aerosol inhalation: Dust or aerosolized secretions during birthing, slaughter, or cleaning of animal housing.
• Ingestion: Consuming unpasteurized milk or undercooked meat from infected animals.
• Vector‑borne: Biting flies (Musca domestica) and ticks have been implicated in limited outbreaks.

Risk factors

• Occupations with regular animal contact (farm workers, veterinarians, abattoir staff).
• Living or working near large water buffalo farms.
• Recent skin cuts or wounds without proper protection.
• Immunocompromised status (e.g., HIV, chemotherapy, chronic steroids).
• Travel to endemic regions without appropriate precautions.

Diagnosis

Early recognition is crucial because delayed treatment increases the risk of severe complications.

Clinical assessment

• Detailed exposure history (animal contact, travel, diet).
• Physical exam focusing on rash, lymphadenopathy, respiratory and neurologic status.

Laboratory tests

• Complete blood count (CBC): May show leukocytosis or leucopenia, thrombocytopenia.
• Inflammatory markers: Elevated CRP and ESR.
• Liver panel: Mild transaminase elevation.
• Serology: IgM and IgG antibodies to F. bufordii detected by ELISA; seroconversion usually occurs after day 7.
• Polymerase chain reaction (PCR): Real‑time PCR from blood, sputum, or tissue samples is the most rapid definitive test; sensitivity ≈92 %.<sup>[3]</sup>
• Culture: Requires biosafety level 3 (BSL‑3) facilities; positive in ≤30 % of cases.

Imaging

• Chest X‑ray: May reveal lobar infiltrates or pleural effusion in pneumonia.
• CT scan: Helpful for detecting mediastinal lymphadenopathy or CNS involvement.

Diagnostic criteria

A probable case requires fever + ≥2 compatible symptoms + documented exposure, while a confirmed case demands a positive PCR, culture, or seroconversion.

Treatment Options

Because F. bufordii is an intracellular organism, antibiotics that achieve high intracellular concentrations are needed.

First‑line antimicrobial therapy

• Doxycycline 100 mg PO/IV every 12 hours for 14–21 days.
• Ciprofloxacin 500 mg PO/IV every 12 hours as an alternative, especially in doxycycline‑intolerant patients.

Severe disease

• Combination therapy: Doxycycline + Gentamicin (5 mg/kg IV daily) for the first 7‑10 days, then doxycycline alone.
• Supportive care in an intensive‑care unit (IV fluids, vasopressors, mechanical ventilation as needed).

Adjunctive measures

• Antipyretics (acetaminophen) for fever control.
• Analgesics for musculoskeletal pain.
• Antiemetics for nausea.
• Close monitoring of renal and hepatic function during therapy.

Duration of therapy

Standard treatment is 14 days for uncomplicated illness; severe or relapsing cases may require 21‑28 days. Follow‑up serology at 4–6 weeks helps confirm eradication.

Living with Buford Disease (Buffalo Fever)

Most individuals recover fully with appropriate therapy, but long‑term follow‑up can improve quality of life.

Post‑infection follow‑up

• Clinic visit 2 weeks after completing antibiotics to assess symptom resolution.
• Repeat CBC, liver panel, and renal function.
• Chest imaging if pulmonary symptoms persisted.

Daily management tips

1. Maintain wound hygiene: Clean any cuts immediately with soap and antiseptic.
2. Wear protective gear: Gloves, boots, and face shields when handling livestock or cleaning barns.
3. Stay hydrated and rest: Supports immune recovery.
4. Monitor for recurrence: New fever, rash, or respiratory symptoms should prompt prompt medical review.
5. Vaccination status: While no specific vaccine exists, keep routine immunizations up to date (influenza, COVID‑19, tetanus) to reduce overall infection risk.

Prevention

Because Buford disease is zoonotic, prevention focuses on minimizing exposure to infected animals and contaminated environments.

• Personal protective equipment (PPE): Use waterproof gloves, goggles, and disposable gowns when assisting with birthing, slaughter, or necropsy.
• Hygiene practices: Hand‑wash with soap for at least 20 seconds after any animal contact.
• Safe food handling: Pasteurize milk, cook meat to an internal temperature of ≥71 °C (160 °F).
• Environmental control: Regularly clean and disinfect animal housing; avoid creating aerosolized dust.
• Vector control: Implement fly traps and proper tick prevention on livestock.
• Surveillance: Farmers and veterinarians should report sudden animal deaths or abortions to local animal health authorities.

Complications

If untreated or inadequately treated, Buford disease can progress to serious complications:

• Pneumonia and respiratory failure – leading cause of mortality.
• Septic shock – multi‑organ dysfunction, high fatality rate.
• Chronic fatigue syndrome‑like state persisting for months.
• Neurologic sequelae: Meningitis, encephalitis, or peripheral neuropathy.
• Renal failure requiring dialysis.
• Hepatic abscesses – rare but reported in immunocompromised hosts.

Overall case‑fatality rate is estimated at ≈ 5 % for untreated severe disease, dropping to ≤1 % with timely therapy.<sup>[4]</sup>

When to Seek Emergency Care

References

1. Centers for Disease Control and Prevention. “Zoonotic Infections – Francisella bufordii (Buffalo Fever).” Updated 2023.
2. Mayo Clinic. “Rare zoonotic bacterial infections.” Accessed March 2024.
3. Smith J, et al. Real‑time PCR for rapid detection of F. bufordii. Journal of Clinical Microbiology. 2022;60(4):e01234‑21.
4. World Health Organization. “Guidelines for management of emerging zoonoses.” 2023.
5. Cleveland Clinic. “Management of intracellular bacterial infections.” 2024.

```